CureVac anticipates to produce COVID-19 vaccine at scale by 2020 end

Published On 2020-09-06 04:30 GMT   |   Update On 2020-09-06 04:30 GMT

Germany: German biotech company Curevac expects to be able to produce the COVID-19 vaccine it is developing at scale by the end of the year, investor Dietmar Hopp told the Handelsblatt business daily.

"We want to make 100 million doses available by the end of the year," said Hopp.

He said he expected regulatory approval in spring or summer of 2021, although limited clearance could come this year to vaccinate people doing jobs that put them at risk of catching COVID-19 or regions with high rates of infection.

"We can't win this race. But we want to win the race to produce the best vaccine and here we have good chances," Hopp said.

Read also: Sanofi, GSK begin human trial of coronavirus vaccine candidate

It is one of a number of firms developing vaccines based on molecules carrying a genetic code called messenger RNA (mRNA) to treat diseases.

Hopp said Curevac may also expand its cooperation with Grohmann, a subsidiary of Elon Musk's electric car maker Tesla, in developing so-called RNA printers that would make it possible to decentralise vaccine production.

Read also: Covid-19 vaccinations could start in early 2021, says German institute





Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News